[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100417429":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":63,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":65,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":65,"enrollmentInfo":78,"targetDuration":65,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":48,"whyStopped":65,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo then Losartan","EXPERIMENTAL","Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.",[13,14],"Drug: Losartan","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Losartan then Placebo","Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.",[13,14],[20,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Losartan","50 mg tablets taken orally",[16,9],[26,27,28],"Cozaar","Angiotensin II Receptor Blocker","Antihypertensive",{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo","Tablets taken orally",[16,9],[34],"Inactive drug",[36],{"name":37,"affiliation":5,"role":38},"Mehrdad Arjomandi, MD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","(415)221-4810","24393","mehrdad.arjomandi@ucsf.edu",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"San Francisco Veterans' Affairs Medical Center","RECRUITING","San Francisco","California","94121","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-122.41942,37.77493,{"lat":58,"lon":57},[61],{"name":37,"role":41,"phone":62,"phoneExt":43,"email":44},"415-221-4810",{"type":64,"investigatorFullName":65,"investigatorTitle":65,"investigatorAffiliation":65,"oldNameTitle":65,"oldOrganization":65},"SPONSOR",null,[67],{"name":68,"class":6},"Flight Attendant Medical Research Institute","100417429","phase-4-secondhand-tobacco-smoke-and-cardiovascular-disease-100417429",false,"NCT04715568","Secondhand Tobacco Smoke and Cardiovascular Disease","Occult Cardiovascular Disease With Chronic Exposure to Secondhand Tobacco Smoke","Inclusion Criteria:\n\n* Must be able to understand and provide informed consent.\n* Adults \\>= 40 years of age.\n* Must have a history of occupational exposure to secondhand tobacco smoke for at least 5 years such as flight attendants who worked for airlines before the smoking ban on aircrafts went into effect or casino workers who worked at casinos with no smoke-free policies.\n* Must have never smoked or have a remote history of light smoking defined as follows:\n\n  * Lifetime smoking history equivalent to \\\u003C 1 pack-year and\n  * No smoking history for \\>= 20 years at the time of enrollment.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol.\n* Subject is pregnant, breast-feeding, or plans to become pregnant.\n* Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).\n* Known intolerance to ACE inhibitor or ARB.\n* History of angioedema.\n* Conventional indication for ACE inhibitor or ARB (e.g., history of myocardial infarction, known cardiomyopathy).\n* Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic while standing or sitting.\n* Known unilateral or bilateral renal artery stenosis higher than 70%.\n* Renal insufficiency (Creatinine Clearance \\\u003C30 mL\u002Fmin by Cockcroft-Gault calculation).\n* Current regular use of NSAIDs defined as daily use on 5 or more days of the week for more than one month.\n* Potassium supplementation or serum potassium level of 5.0 milliequivalents (mEq)\u002FdL or higher at V1.\n* Current use of a potassium sparing diuretic.\n* History of clinically overt cardiovascular disease including: stable or unstable angina; chest discomfort and dyspnea with baseline exertion; symptomatic coronary artery disease (as defined by history of abnormal stress test; cardiac catheterization showing \\>70% coronary artery stenosis; history of revascularization; pathologic Q waves on EKG); poorly controlled resting hypertension (SBP\\>160\u002F DBP\\>95); congestive heart failure (CHF) (as defined by left ventricular ejection fraction (LVEF) \\\u003C55%; physical exam findings of CHF; symptomatic pulmonary edema); significant (\\>mild) valvular heart disease; congenital heart disease; cardiac arrhythmias including frequent premature atrial or ventricular contractions (\\>5 per minute).\n* History of clinically overt pulmonary disease that may interfere with study procedures, including: greater than mild asthma, COPD, emphysema, chronic interstitial lung disease, and pulmonary hypertension.\n* Neuromuscular disorders or physical disability to perform exercise testing using an ergometer.\n* Significant history of recreational drug use other than marijuana as defined by: recreational drug use within the last 30 years of recruitment (or) recreational drug use at a frequency of more than once a month before 30 years.\n* Marijuana use more than once a week.\n* Other uncontrolled chronic illnesses which in the judgment of the study physician would interfere with completing study procedures.\n* Failure to keep screening appointments or other indicators of non-adherence.\n* Concomitant participation in another interventional study.\n* Subjects with BMI \\\u003C15 or \\>40 kg\u002Fm2.\n* MRI Scan Participation Exclusion Criteria - The participants will be excluded from the MRI portion of the study if they have a metallic object embedded or implanted in their body that is incompatible with Magnetic Resonance (MR) scanning, including MR incompatible pacemaker or defibrillator.","ALL","40 Years",{"count":79,"type":80},100,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.",[86,87],"Cardiovascular Diseases","Hypertension",[89],"Second Hand Tobacco Smoke","2026-08-17",{"date":92,"type":93},"2026-08-19","ACTUAL",{"date":95,"type":93},"2021-03-30",{"date":97,"type":80},"2026-12-31",{"name":5,"class":6},1]